Anemia Clinical Trial
— LISAOfficial title:
Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya: an Open Label Randomized Trial to Compare With an Oral Contraceptive Regimen That Provides Supplemental Ferrous Fumarate Tablets
Verified date | May 2024 |
Source | FHI 360 |
Contact | David Hubacher, PhD |
Phone | 9195447040 |
dhubacher[@]fhi360.org | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Women with mild/moderate anemia who are seeking contraception will be randomized to a levonorgestrel (LNG) intrauterine system (IUS) or an LNG/ethinyl estradiol (EE)/ferrous fumarate combined oral contraceptive (COC) regimen and followed prospectively for 18 months. Approximately 600 participants will be enrolled. The primary hypothesis is that the mean change in hemoglobin concentration will be significantly higher in the group assigned to the LNG IUS compared to the group assigned to COCs
Status | Recruiting |
Enrollment | 600 |
Est. completion date | February 2026 |
Est. primary completion date | February 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Provide sequential oral and written consents to screen for eligibility and enroll - Female, aged 18-50 - Desire to use contraception or possibly switch methods - Possession of a cell phone and willingness to be contacted - Confirmatory low hemoglobin (minimum of 87 g/L and maximum of 126 g/L) taken 1 to 4 weeks after the initial test - Regularly menstruating (at least once every 35 days) - At least 6 weeks postpartum - Willingness to agree to study procedures - Willingness to be randomized to treatment - Willingness to use assigned hormonal contraceptive for 18 months Exclusion Criteria: - Severe anemia (hemoglobin < 86 g/L) - Currently pregnant based on urine pregnancy test and failure to rule out possible pregnancy according to WHO guidelines - Surgically sterilized or had a hysterectomy - Participated previously in this study by being randomized to contraceptive - Currently using a subdermal contraceptive implant and does not wish to have it removed - Currently using an LNG IUS - Currently receiving treatment for anemia - Any of the following previously diagnosed disorders: hemosiderosis, hemochromatosis, hemolytic anemia - Known allergic reactions to oral contraceptives or LNG IUS - Currently receiving an investigational (unapproved) drug in another study - Any condition (social or medical) which in the opinion of the investigator would make study participation unsafe - Intending to become pregnant in the next 18 months - Mucopurulent cervicitis - Pelvic inflammatory disease - Other medical contraindications to treatment, according to WHO Medical Eligibility Criteria (categories 3 or 4) |
Country | Name | City | State |
---|---|---|---|
Kenya | Kangemi Health Center | Nairobi |
Lead Sponsor | Collaborator |
---|---|
FHI 360 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Kenya,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in hemoglobin | Measured in g/L | 18 months | |
Secondary | Change in serum ferritin | Measured in mcg/L | 18 months | |
Secondary | Change in number of days of bleeding/spotting in a month | A bleeding day is defined as a day when blood loss requires the use of sanitary protection with a tampon, pad or pantyliner. A spotting day is a non-bleeding day with minimal blood loss that does not require new use of any type of sanitary protection, including pantyliners | 18 months | |
Secondary | Contraceptive method discontinuation | Discontinuation is defined as either LNG IUS removal or 5 or more consecutive days without taking an oral contraceptive pill | 18 months | |
Secondary | Contraceptive satisfaction | Level of satisfaction with the products will be recorded on a 5-point Likert scale: very satisfied, somewhat satisfied, neutral, somewhat dissatisfied, very dissatisfied. | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |